Category Archives: Raising C Diff Awareness Education

November Is C. diff. Awareness Month: We Can Make a Difference Together Worldwide

In joint efforts with the C Diff Foundation Advocates and organizations dedicated in preventing and treating life-threatening Clostridioides difficile (C. diff., C. difficile) infections,  we express our gratitude and congratulate the State of Arizona, Arkansas, Idaho, Michigan, Minnesota, New Mexico,  Pennsylvania, West Virginia,  Wisconsin, to name a few, to date  for declaring November “Clostridioides difficile (C. diff., C. difficile) Awareness Month.

The Proclamations approved serve to heighten awareness of the impact this disease has on patients across the United States. The infection, which has been labeled an urgent national health threat by the Centers for Disease Control (CDC), results in 500,000 infections each year and is directly responsible for approximately 29,000 patients who died within 30 days of the initial diagnosis of C. difficile.  Of those, about 15,000 deaths were estimated to be directly attributable to C. difficile infections.

 

 

 

 

 

An excerpt from USA Today article published in 2012:    Deaths and illnesses are much higher than reports have shown. In March, the  CDC  said in a report that the C difficile infection kills 14,000 people a year. But that estimate is based on death certificates, which often don’t list the infection when patients die from complications, such as kidney failure.  Hospital billing data collected by the federal Agency for Healthcare Research and Quality shows that more than 9% of C. diff-related hospitalizations end in death — nearly five times the rate for other hospital stays. That adds up to more than 30,000 fatalities among the 347,000 C. diff hospitalizations in 2010. Thousands of patients are treated in nursing homes, clinics and doctors’ offices.

“We’re talking in the range of close to 500,000 total cases a year,” says Cliff McDonald, a C. diff expert, and senior science adviser in the CDC’s Division of Healthcare Quality Promotion. And annual fatalities “may well be … as high as 30,000.”

* AHRQ News and Numbers provides statistical highlights on the use and cost of health services and health insurance in the United States.

http://archive.ahrq.gov/news/newsroom/news-and-numbers/012512.html

In the USA:  Nearly half a million Americans suffer from Clostridium difficile (C. diff.) infections in a single year according to a study released February 25, 2015, by the Centers for

Not only in November, but every day of the year it is our time to make a difference!  Most patients and their families, until their diagnosis, are not familiar with this infectious disease.  When they tell their friends and family, their friends and family have never heard of a C. difficile (Clostridium difficile, C. diff., CDI)  infection before.

Sometimes, even when they are told by their doctors of this diagnosis, the doctors can be largely unfamiliar with the impact of this infection and the treatments readily available. This is astonishing. Why? Because a C. diff. infection impacts individuals differently than it did decades ago.  The re-occurrence rate is greater today than it was in previous years.   C.difficile infections are not only acquired by a hospital stay but can be community-acquired.  It is a global diagnosis and this infection is not isolated in the senior population, however; seniors remain in the higher risk category of acquiring this infection.

FACT:  About a C. diff. infection  — Over 41 individuals lose their life to a Clostridioides difficile infection in the United States of America alone each day — C. difficile has no boundaries — It can be acquired by anyone –  at any location and at any age.

Every year we work together to change the level of C. difficile awareness worldwide. Every year we make a difference. Every day of every year we share information through education and advocacy for patients and continue to raise awareness of Clostridioides difficile infection (C. diff., C. difficile, CDI) prevention, treatments, clinical trials, and environmental safety  — further than the day before.

“None of us can do this alone – All of us can do this together.”

Clostridioides difficile (C. diff. C. difficile, CDI) has had an immeasurable impact on our families, in our communities, in our countries.  It is a leading Healthcare-associated infection (HAI) yet awareness of Clostridioides difficile remains quite low among the general public worldwide.

Help us change this.  Contact us and join us TODAY!

Take Action

  • Draft a letter to your State Governor requesting a Proclamation for November dedicated for promoting Clostridium difficile Infection Awareness.
  • Create Your Own Fundraiser!
  • Contact kathy@cdifffoundation.org to get started on the fundraiser of your choice.

Awareness Tools

  • Share the C Diff Foundation brochure  (request your copies by e-mail)  A great guide to explain details about a C. diff. infection and data on C. diff. prevention, treatments, and environmental safety available.
  • The Clinical Trials Page showcases Clostridium difficile prevention and treatment clinical trials available and research-driven results.
  • Personal Stories on C. diff. Survivors Alliance  allow you to share your story, to help raise awareness about C. difficile infections, and to help raise funds for C Diff Foundation www.cdifffoundation.org
  • Share  C.diff. Global Community Support session information which is FREE and available across the USA and accessible from 57 countries to learn more about a C. diff. infection, Nutrition, and to speak with health care providers and fellow-C.diff. survivors to gain knowledge and have questions answered.

Social Media Involvement

Please join us and share YOUR story. Use these November Awareness campaign hashtags to spread awareness for November Is Clostridioides difficile (Clostridium difficile, C.diff., C.difficile, CDI) Infection Awareness Month.

To obtain printed literature to share with your family, friends, colleagues, in your community and with your health care providers  — along with  a “November Is C. diff. Awareness Month”  Magnet, please contact the C Diff Foundation’s Main Office (727) 205-3922 or email your request:  info@cdifffoundation.org

#CdiffInfectionAwareness

(Facebook)  (Twitter)

#CdiffNovemberAwareness

(Facebook)  (Twitter)

# # # # # # # # # # # # # # # # # # # # # # #

NOVEMBER IS ALSO U.S. Antibiotics Awareness Week

November 18 – 24, 2019

 

 

 

CDC’s educational effort, Be Antibiotics Aware: Smart Use, Best Care, is the year-round effort to improve antibiotic prescribing and use and combat antibiotic resistance.

In November the  annual campaign  developed by the Centers for Disease Control and Prevention (CDC) :

Share the resources of countries Raising Antibiotic Awareness Worldwide

https://www.cdc.gov/antibiotic-use/week/get-involved.html

Antibiotic Awareness Week

https://www.england.nhs.uk/2019/10/world-antibiotic-awareness-week-18-22-november/

 

How do Antibiotics cause C. diff.?  The antibiotics cause a disruption in the normal intestinal flora which leads to an overgrowth of C. difficile bacteria in the colon. Leading antibiotics are known to disrupt the normal intestinal flora.

As far back as November 2012, the CDC started sharing a public announcement regarding antibiotic use: Colds and many ear and sinus infections are caused by viruses, not bacteria. Taking antibiotics to treat a “virus” can make those drugs less effective when you and your family really need them. Limiting the usage of antibiotics will also help limit new cases of CDI.
*Always discuss the symptoms and medications with the treating Physician/Healthcare Provider.

 

Your participation makes a BIG difference around the globe.

WEBINAR: Improving Care Transitions in Clostridioides difficile Infection November 14th, 2019 at 2:00 p.m. EST

WEBINAR

Improving Care Transitions in Clostridioides Difficile Infection

Thursday, November 14, 2019 at 2:00pm Eastern/11:00am Pacific

Intended Audience: Physicians, Nurse Practitioners, Physician Assistants, Nurses, Pharmacists and Case Managers

 Overview: With advances in Clostridioides difficile infection (CDI) treatment and recurrence prevention, and recently updated IDSA/SHEA guidelines, remarkable potential exists to improve CDI patient outcomes through effective interventions at critical transition points.

Join CDI experts Sahil Khanna, MD, MBBS, and Kevin Garey, PharmD, MS, FASHP, for an interactive webinar highlighting core concepts and strategies from the CDI Transitions of Care (TOC) Pathway. The CDI TOC Pathway was developed in partnership with the National Transitions of Care Coalition (NTOCC) to arm system leaders and CDI care teams with essential interventions and tools to ensure safe and effective TOCs for patients with CDI across care settings.

Agenda:

  1. Overview of the Clostridioides difficile infection (CDI) Transitions of Care Pathway
  2. How Do Ineffective Care Transitions Impact Patients with CDI?

III. Assessing CDI Risk and Implementing Diagnostic Stewardship

  1. Advances in the Treatment of Primary and Recurrent CDI
  2. Engaging CDI Patients and Caregivers in Effective and Safe Care Transitions

Expert Faculty:

Sahil Khanna, MBBS

Kevin W Garey, PharmD, MS, FASHP

Michael R Stinchon, Jr, RPH

 Offering 1.0 hour of ACCME, AAPA, AANP, ACPE, ANCC, and CCM credit.

Click on the graphic below to be directed to the webinar on

November 14th at 2:00  EST

 

 

 

 

 

 

Supporter statement: This activity is provided by PRIME Education. There is no fee to participate. This activity is supported by an educational grant from Merck & Co. Inc.

May Is National Walking Month and Time For the Annual Global C.diff. (CDI) Awareness 2K Walk

With its fresh Spring mornings and lovely long evenings – not to mention an extra long weekend – it’s no wonder that May is the official National Walking Month. Whether you prefer leisurely strolls or challenging hikes, our four park surroundings have a  walk for everyone to raise awareness of C.diff., walk for a cause in all locations.   Lace up your walking shoes and venture out to Milton A. Votee Park, Teaneck, N.J., Charlestown Township Park, Phoenixville, PA., Sims Park, New Port Richey, FL.,  on Saturday, May 18th to experience one of  these 3 C.diff. Awareness 2k walks.

 

Registration is open until May 8th.   3rd Annual Global C.diff. Awareness 2K Walks.

The USA events will take place on Saturday, May 18, 2019 from 8 a.m. – 12 p.m.

 

2019 CDIFF Global Awareness Walk

Dr. Martha Cloakie, PhD will be leading the walk in Leicester, U.K. on Friday, May 17, 2019.

All registered awareness walkers will receive t-shirts, giveaways, and educational material while introducing the communities to the resources available. C.diff. infections are one of the leading healthcare-associated infections facing local communities.

Registration is $20.00 per walker and children 10 years of age and under walk free. https://cdifffoundation.org/3rdannualwalk/

Proceeds from the events will benefit the C Diff Foundation’s mission educating and advocating for C.difficile infection prevention, treatments, clinical trials,  environmental safety, sepsis, and antibiotic awareness worldwide.

According to the Centers for Disease Control and Prevention (CDC), a Clostridioides difficile infection (C.difficile), (formally known as Clostridium difficile) “has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone.”

Statistics provided by the CDC suggest that C. difficile cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

We sincerely thank Vedanta Biosciences, Inc. for being the Diamond Sponsor of the 3rd Annual Global C.diff. Awareness 2K Walks. Vedanta Biosciences, Inc. is dedicated to finding treatments for patients with serious infections and immune diseases. Vedanta develops medicines made of consortia of bacterial strains which are selected to effect robust and durable changes in a patient’s gut microbiota. In contrast to fecal transplants or administration of fecal fractions, Vedanta’s medicines are pure, uniform compositions of bacteria manufactured from clonal cell banks, bypassing the need to rely on direct sourcing of fecal donor material of inconsistent composition. Vedanta is currently enrolling patients with recurrent C. difficile infections (CDI) in its CONSORTIUM study to evaluate VE303, an investigational treatment for CDI.

Our gratitude to all of the sponsors for their support and partnering with the C Diff Foundation in raising C. diff. awareness worldwide:

Gold Sponsors:    Rebiotix, Pfizer, Ferring Pharmaceutical

Silver Sponsor:    CutisPharma

Bronze Sponsor: Finch Therapeutics

If you have any questions,  please contact one of our staff members at

(727) – 205 – 3922  or e-mail:  info@cdifffoundation.org

We look forward to walking with you on May 18th!

Follow Us On Twitter:   #CdiffWalks2019

November IS C.diff. (Clostridium difficile, C.difficile) Infection Awareness Month – Changing Lives – Saving Lives – Making a Difference With You

YOU CAN make a difference!

How?

Let us show you the ways……

It is as simple as sharing a graphic provided below or by sharing the website which is complete with C.diff. Infection key points on  Prevention, Treatments available, Clinical Trials in progress, Environmental Safety, Infection Prevention, Support, Healthcare Provider updates, Patient and Family resources and much more.

www.cdifffoundation.org

The valuable information located on the website can answer questions that develop during a C.difficile infection.  The website also provides important contact information with  listings of free patient/family programs.

It is empowering to share the information through the printed literature available.  The information will be mailed  to a physical address (not e-mailed) and can be shared with friends, family, health care professionals, and within your community.

Having a conversation —- sharing your story, accompanied with the facts found on the website explaining C.diff. prevention, treatments available, clinical trials, environmental safety, and support worldwide, is both appreciated and powerful.

To receive complimentary brochures, magnets and additional information – please complete the form below:

You are invited to join us in advocating for Cdiff Awareness during the month of November and every month after that because educating and advocating  for C.diff. prevention, treatments available, clinical trials, environmental safety, and support is important every day of the year.

Become a Volunteer Patient Advocate today

Thank you for considering taking steps forward and walking with us to witness a global change and decrease in newly diagnosed Clostridium difficile infections worldwide.

With our sincere gratitude 💚

The Committee Chairs, Patient Advocates, and Members of the C Diff Foundation Worldwide

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  • Please Note:  ALL personal information submitted will never be shared or sold by the C Diff Foundation.  Name, Address, e-mail address will be utilized for the purpose set forth in this message.
  • Thank you .

 

C Diff Foundation’s Health Education Clinic Has Flourished Over Recent Year With the Support From Nursing Students

On Wednesday, August 1st the senior Nursing students from
Rasmussen College attended the Foundation’s
bi-weekly Health Education Clinic in Florida where they were given the opportunity to expand their knowledge base focused on C.difficile (C.diff.)  Infections, Clinical Trials, Sepsis,  and
Antibiotic Stewardship while utilizing their skills with hands on practice.  The students add a new public health topic each month during the Health Education Clinic that benefit the local residents of Pasco County, Florida. The Health Education Clinic began in June 2017 and has proven beneficial to the local citizens to learn more about C.difficile infection prevention, treatments, clinical trials, environmental safety, support, Sepsis, and other leading Healthcare-acquired infections — to name a few MRSA, VRSA.  The Nursing Students, with their clinical faculty member,  introduce topics of hydration, nutrition, diabetes, hypertension, and display their proficiency in blood-pressure monitoring during clinic.

“It has been gratifying to witness the positive changes taking place in the resident’s health over the past year.  We extend our gratitude to the Rasmussen Colleges for incorporating our community program into their student’s curriculum/clinical experience to learn more about our mission from our members and for providing public health educational material to the local community,” stated Nancy Caralla, Founding President of the C Diff Foundation. “The program is mutually beneficial with outstanding results being produced.”

 

 

 

 

 

 

 

 

 

 

 

 

We are grateful for Rasmussen College, and their Nursing Students, for the continued support of this community outreach program.

Merck and Premier Applied Sciences Will Develop Software To Provide C.difficile Infection Education and Provide Surveillance

Merck & Co is working a major US hospital provider on a new software system that could help tackle the threat from healthcare-associated infections, the leading HAI:   C. diff.  infections.

 

 

 

The pharma company’s deal with Premier will see the partners develop and test the combination of a software-based platform and a coordinator to provide surveillance, consultation, support and education to patients with Clostridium difficile infection (C. diff).

Sam Bozzette, MD, chief scientist of Premier’s retrospective and interventional research division Premier Applied Sciences, said: “By increasing clinician and patient knowledge of this often prolonged, and sometimes deadly infection, and developing and testing a software-based application to help reduce the recurrence of C. diff. infection by improving follow-up and management, we believe there is a strong potential to make a real difference to address this critical public health problem.”

Sam Bozzette, MD, PhD, vice president and chief scientist of its retrospective and interventional research division, Premier Applied Sciences.  An internationally-recognized researcher and physician executive, Dr. Bozzette provides strategic clinical, analytical and operational direction to further grow the Premier Applied Sciences research business and improve the overall quality, safety and cost-effectiveness of care.  “Dr. Bozzette is a leader in medical and social sciences, and has more than 25 years of experience working with academic and non-profit healthcare providers to improve clinical decision-making practices, care delivery efficiency and effectiveness, and population health management,” said Leigh Anderson, chief information officer at Premier. “We are thrilled to have him on board to lead Premier’s data-driven research efforts to set new standards in care delivery through strategic partnerships with healthcare industry leaders across the U.S.”

Premier Applied Sciences, formerly known as Premier Research Services, combines data and analytics with objective clinical outcomes analyses, and partnerships with health systems, life sciences companies, academic institutions and professional societies to develop, teach, test and research care delivery practices and real-world interventions for healthcare improvement. It offers real-world research and analytics, retrospective research, healthcare education, clinical trial innovation and data licensing services.

Resources:  https://pharmaphorum.com/news/merck-co-software-c-diff-infections/

https://www.premierinc.com/dr-sam-bozzette-joins-premier-inc-lead-research-division/

The work expands Merck’s chronic disease work with Premier, which has seen them co-develop and test solutions that help promote wellness and prevention for specific groups of at-risk patients since 2016.

Raquel Tapia, associate VP, hospital/specialty marketing at Merck, said: “Combining the technical capabilities of Premier and the therapeutic area expertise of Merck has been instrumental in our ability to address these difficult healthcare challenges.

“By testing the solutions in real-world settings and learning from our growing knowledge base, we’re confident that our work together will help patients.”

The partners’ goal is to increase patient access to healthcare services, raise awareness of how to decrease patient risk of recurrence and help patients identify if they are having a recurrence.

The proposed C. diff software intervention will be tested within volunteer Premier member health systems. The firm current has an alliance of around 3,900 US hospitals and health systems and a further 150,000 or so healthcare providers and organizations.

C. diff infections cause serious and life-threatening diarrhea and have become one of the most common microbial cause of healthcare-associated infections in US hospitals. It’s thought that C. diff infections affect approximately half a million people and add $4.8 billion to US healthcare costs each year.

CutisPharma Partners With C Diff Foundation To Support C.difficile Infection Awareness and Advocacy Efforts

 

CutisPharma and the C Diff Foundation announced the launch of a partnership beginning on November 1, 2017, the first day of Clostridium difficile awareness month.  As part of the partnership, CutisPharma awarded an unrestricted grant to the Foundation to further support its awareness efforts.

“We are pleased to partner with the C Diff Foundation and support its education and advocacy efforts benefiting patients impacted by Clostridium difficile Infection,” said Neal I. Muni, MD, MSPH, Chief Executive Officer of CutisPharma.  “It’s our hope that our work together can make positive strides in building awareness of this life-threatening condition that affects over a half-million patients in the United States annually.”

The nonprofit C Diff Foundation is dedicated to supporting global public health initiatives for Clostridium difficile Infection (CDI), also called C. difficile or C. diff – for infection prevention, treatments and environmental safety.

“We are very thankful for CutisPharma’s support of our foundation’s efforts,” said Nancy Caralla, Foundress and Executive Director of the C Diff Foundation, who is both a nurse and a three-time C. difficile survivor who also lost her father to a C. difficile infection.  “CutisPharma’s mission to improve the lives of patients with unmet medical needs is aligned with our foundation’s goals, and we look forward to partnering with Neal and his team to further our education and advocacy efforts on behalf of patients and survivors.”

CutisPharma has undertaken several initiatives to expand from its traditional base of making compounding kits for pharmacists, including the development and commercialization of FDA-approved drugs. The filing of the Company’s first FDA New Drug Application earlier this year, by its RM Therapeutics subsidiary, was a key milestone in the Company’s expansion goals.

About CutisPharma

CutisPharma, Inc., based in Wilmington, Mass., is a privately held, specialty pharmaceutical company that has historically developed and distributed kits used by pharmacists to safely create compounded medications for nearly 20 years.  The Company’s products include oral solutions and suspensions, such as antimicrobials, mouthwashes, and PPIs; topicals, including hydrocortisone; and suppositories, including progesterone VGS.  CutisPharma’s FIRST Unit-of-Use Kits have benefited millions of patients who are unable to swallow conventional oral dosage forms such as tablets and capsules and whose needs are not served by commercially available therapies.  For more information, visit www.cutispharma.com.